Investors

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News

DateTitle
09/16/16Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective September 16, 2016, the compensation committee of the company’s board of directors granted 11 new employees options to purchase an aggregate of 127,000 shares of the company’s common stock with a per share exercise price of $30.98, the closing trading price on the grant date. In addition, 100,000 shares of stock were granted to a Senior Vice President, Quality Assura... 
09/01/16Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September 
REDWOOD CITY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences in September, both being held in New York. A company presentation is scheduled at Baird’s 2016 Global Healthcare Conference on Wednesday, September 7th at 9:40 a.m. ET Management participation in a fireside chat is scheduled at the Morgan Stanley Global Healthcare Conference on Tuesday, Se... 
08/31/16Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective August 31, 2016, the compensation committee of the company’s board of directors granted 6 new employees options to purchase an aggregate of 80,000 shares of the company’s common stock with a per share exercise price of $29.77, the closing trading price on the grant date.  The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commence... 
08/09/16Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results
Continued execution on multiple fronts positions the company strongly for the second-half of 2016 and beyond REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reported financial results and reviewed corporate events for the second quarter ended June 30, 2016. Corporate Highlights for the Second Quarter 2016 Include: Immunology (anti-TNF) therapeutic franchise: CHS-1420 (adalimumab (HUMIRA®) biosimilar) Received f... 
View All

Upcoming Events

There are currently no events scheduled.
View All

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

CHRS (Common Stock)

ExchangeNASDAQ (US Dollar)
Price$30.00
Change (%) Stock is Down 0.88 (2.85%)
Volume196,835
Data as of 09/23/16 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet